Krystal Biotech, Inc.
KRYS
Rankning i aktier
#2129
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on... Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Aktiekurs
$326.41
Senast synkroniserad: 2026-10-20
Marknadsvärde
$9.66B
Förändring (1 dag)
1.92%
Förändring (1 år)
71.09%
Land
US
Handel Krystal Biotech, Inc. (KRYS)
Kategori
Healthcare
Antal utestående aktier för Krystal Biotech, Inc. (KRYS)
Antal utestående aktier per June 2026: 29.53M
Enligt de senaste finansiella rapporterna och aktiekursen för Krystal Biotech, Inc. är det aktuella antalet utestående aktier 29.53M. I slutet av December 2023 hade företaget 27.15M utestående aktier. Antalet utestående aktier påverkas vanligtvis av aktiesplit och återköp av aktier.
Historik över utestående aktier för Krystal Biotech, Inc. (KRYS) från 2016 till 2026
Utestående aktier vid slutet av varje år
| År | Utestående aktier | Ändra |
|---|---|---|
| 2026 (TTM) | 29.53M | 3.28% |
| 2024 | 28.59M | 5.30% |
| 2023 | 27.15M | 6.52% |
| 2022 | 25.49M | 14.85% |
| 2021 | 22.20M | 18.15% |
| 2020 | 18.79M | 18.15% |
| 2019 | 15.90M | 41.93% |
| 2018 | 11.20M | 108.99% |
| 2017 | 5.36M | 25.38% |
| 2016 | 4.28M | 0.00% |
Utestående aktier för liknande företag eller konkurrenter
| Företag | Utestående aktier | Skillnad | Land |
|---|---|---|---|
| 253.90M | 759.83% |
US
|
|
| 396.00M | 1,241.05% |
US
|
|
| 478.91M | 1,521.84% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | 110.59% |
NL
|
